© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Brain Cancer
Study Aims to Explore Treatment Modalities in Patients With Multiple Brain Metastases
September 25, 2020
In an interview with Targeted Oncology, David Roberge, MD, discussed the role of radiation treatment in patients with brain metastases and the clinical trial evaluating treatment approaches for patients with more than 5 brain metastases.
Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes
September 22, 2020
Results from the DUNE trial of durvalumab added to tremelimumab in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins showed limited activity, according to a presentation held during the 2020 European Society of Medical Oncology Virtual Congress.
Neuro-Oncologists Await Late-Phase Clinical Trial Exploration of Enzastaurin in Glioblastoma
September 17, 2020
Enzastaurin is on track to serve an unmet medical need in the treatment landscape of glioblastoma. Neuro-oncologists are waiting on the launch of an important clinical trial to further demonstrate the efficacy of the drug.
FDA Grants Orphan Drug Designation to RNL in Recurrent Glioblastoma
September 02, 2020
The FDA has granted an Orphan Drug designation to rhenium nanoLiposomes for the treatment of patients with recurrent glioblastoma.
FDA to Release Guidance on Evaluating Cancer Drugs for Brain Metastases
August 31, 2020
The FDA announced draft guidance, which provides recommendations for the design of clinical trials and biological products for product labeling for those with brain metastases regulated by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
FDA Grants Fast Track Designation to Paxalisib in Glioblastoma
August 20, 2020
The FDA granted a Fast Track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma with unmethylated MGMT promotor status who have completed initial radiation and temozolomi
Modern Therapies Offer a Way to Reach the Brain in HER2+ Metastatic Breast Cancer
August 14, 2020
In an interview with Targeted Oncology, Stephanie Weiss, MD, reviewed the treatment landscape for HER2-positive metastatic breast cancer and gave her predictions on how the paradigm will evolve for patients with brain metastases now that tucatinib has demonstrated efficacy.
Pooled Analysis Reveals Long-Term Effect on QoL and Cognitive Outcomes From Radiation for Brain Metastases
August 14, 2020
In the first pooled prospective study to show the long-term outcomes of cranial radiation in patients with limited brain metastases, it was observed that whole-brain radiotherapy was associated with worse cognitive outcomes and mixed quality of life compared with stereotactic radiosurgery for these patients over time, according to a presentation from Joshua Palmer, MD, at the 2020 Virtual Conference on Brain Metastases.
Radiosurgery Improves Clinical Outcomes in Brain Metastasis Treatment
August 14, 2020
Joshua Palmer, MD, discusses a pooled analysis of 2 randomized clinical trials that compared how clinical outcomes and quality of life were impacted with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases.
Tucatinib Combination Demonstrates Multiple Positive Responses in HER2-Positive Metastatic Breast Cancer
August 14, 2020
Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib in combination with trastuzumab and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB trial.